To evaluate the safety and clinical efficacy of the domestic "Jingfeng" single-port robot-assisted laparoscopic extraperitoneal radical prostatectomy (SP-RARP) in the treatment of localized prostate cancer (PCa).

A retrospective analysis was conducted on the clinical data of 10 patients who underwent extraperitoneal SP-RARP at the First Affiliated Hospital of Anhui Medical University in March 2025. The surgical approach was extraperitoneal SP-RARP. The data were collected included patients' age, body mass index (BMI), prostate volume, preoperative prostate-specific antigen (PSA), Gleason score, and perioperative indicators such as surgery time, blood loss, pain score, and ventilation time.

All 10 patients were successfully completed the surgery, with a median age of 69(60, 77) years. The median BMI was 23.9(23.3, 24.8) kg/m².The median preoperative PSA was 9.5(6.3, 13.5) ng/mL, and the median preoperative prostate volume was 32.4(23.3, 36.9) cm³. In terms of perioperative indicators, the median surgery time was 148(124, 195) minutes, the median intraoperative blood loss was 75.0(47.5, 97.5) mL, the median ventilation time was 1.5(1.0, 2.0) days, the median time to liquid diet recovery was 2(1, 2) days, and the median hospital stay was 4.0(3.0, 4.3) days. The postoperative pathological margins of all patients were negative, and there were no intraoperative conversions to open surgery or severe complications.

Domestic "Jingfeng" single-port robot-assisted extraperitoneal radical prostatectomy is a safe and effective minimally invasive surgical technique. However, further large-scale, multi-center, randomized controlled trials are needed to validate its efficacy and safety.